Mythic Therapeutics Announces Publication of Preclinical Data Highlighting the Differentiating Properties of MYTX-011 in Molecular Cancer Therapeutics

WALTHAM, Mass.--(BUSINESS WIRE)--Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced the publication of preclinical data highlighting the differentiating properties of its investigational cMET-targeting ADC, MYTX-011, in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR).

“The potential of novel ADC technologies to enhance payload delivery to tumors is relatively underexplored compared to advances in linker-payload technology and target selection,” said Nimish Gera, Ph.D., lead author of the paper and Scientific Co-founder, Vice President of Biologics at Mythic. “We believe that engineering pH-dependent binding could be a particularly compelling strategy for ADCs targeting medium to low levels of cMET expression in patients. We’re pleased to publish this study illustrating how the properties of MYTX-011, including its potential for increased on-target potency, enhanced tolerability, longer half-life and higher efficacy, may enable this therapy to serve patients with a broad range of cMET expression who otherwise have limited treatment options. We look forward to continuing to evaluate MYTX-011 in our ongoing Phase 1 clinical trial.”

The study demonstrated that incorporation of pH-dependent binding in the antibody component of a cMET targeting ADC can overcome the requirement for high cMET expression on tumors, an innovation that has the potential to benefit a broader population of patients with lower cMET levels. MYTX-011 drove four-fold higher net internalization than a non-pH engineered parent ADC in non-small cell lung cancer (NSCLC) cells and showed increased cytotoxicity against a panel of cell lines from various solid tumors, including head and neck, gastric, pancreatic, esophageal, bladder, kidney and skin cancer. A single dose of MYTX-011 showed at least three-fold higher efficacy than a benchmark ADC in mouse xenograft models of NSCLC ranging from low to high cMET expression. Additionally, MYTX-011 showed improved pharmacokinetics over parent and benchmark ADCs. In a repeat dose toxicology study, MYTX-011 exhibited a toxicity profile similar to other MMAE-based ADCs.

MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).

About MYTX-011

MYTX-011, an investigational cMET-targeting antibody-drug conjugate (ADC), leverages Mythic’s innovative FateControl™ technology, which allows ADCs to actively navigate inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles. MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).

About Mythic Therapeutics

Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ technology aims to enhance ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the diseases and patient profiles that could be treated with Mythic’s ADCs. The company’s major investors include Venrock, Viking Global Investors, and First Round Capital.

For more information, visit: www.mythictx.com and follow on LinkedIn.